肿瘤细胞治疗研究
英文原题：CAR-NK cell for gynecological cancers: immune microenvironment remodeling and immunotherapeutic strategies.
妇科恶性肿瘤，包括卵巢癌、宫颈癌和子宫内膜癌，构成了重大的全球健康负担，显著增加了女性的发病率和死亡率。
妇科恶性肿瘤，包括卵巢癌、宫颈癌和子宫内膜癌，构成了巨大的全球健康负担，显著增加了女性的发病率和死亡率。尽管治疗策略取得了进展，但由于晚期检测和对标准治疗耐药等挑战，许多患者的预后仍然不理想。嵌合抗原受体（CAR）工程化自然杀伤（NK）细胞的出现引入了一种前沿的免疫治疗选择。本综述深入探讨了CAR-NK细胞的发展，重点阐述其来源、设计方法以及在妇科癌症管理中的应用。同时审视了当前的障碍，并概述了提高基于CAR-NK细胞疗法的有效性和安全性的创新策略。此外，我们讨论了前瞻性进展，强调了持续研究和技术创新对于充分释放CAR-NK细胞在抗击妇科癌症中潜力的重要性。
Gynecological malignancies, including ovarian, cervical, and endometrial cancers, represent a substantial global health burden, contributing significantly to morbidity and mortality among women. Despite advancements in therapeutic strategies, outcomes for many patients remain suboptimal due to challenges such as late-stage detection and resistance to standard treatments. The advent of chimeric antigen receptor (CAR)-engineered natural killer (NK) cells has introduced a cutting-edge immunotherapy option. This review provides an in-depth exploration of the development of CAR-NK cells, emphasizing their sources, design methodologies, and applications in managing gynecological cancers. It also examines current obstacles and outlines innovative strategies to improve the effectiveness and safety of CAR-NK cell-based therapies. Furthermore, we discuss prospective advancements, highlighting the importance of ongoing research and technological innovation to unlock the full potential of CAR-NK cells in the fight against gynecological cancers.
MEMBER ACCOUNT
登录成功会直接打开下一页。
